Suitable for a wide range of tumor types, innovative peptide-conjugated drugs to enhance the effect of immunotherapy

Cybrexa Therapeutics today announced that preclinical cancer models have demonstrated that the peptide-conjugated drug (PDC) CBX-12 under development can enhance the effectiveness of immune checkpoint inhibitors

Point inhibitors combined with chemotherapy are standard treatments for many solid tumors, but bone marrow suppression associated with chemotherapy can reduce the efficacy of immunotherapy

So, is there any way to specifically target a wide range of tumor types while avoiding toxicity?

One of the characteristics of all tumors is the acidic microenvironment

This selective targeting of tumor cells' mechanism of action avoids the toxicity associated with the therapy's attack on healthy cells

▲The mechanism of using low pH insert peptides to deliver anti-cancer drugs to tumor cells (picture source: Cybrexa official website)

The researchers used a mouse model of colorectal cancer to further evaluate the effect of CBX-12 on the efficacy of PD-1 and CTLA4 immune checkpoint inhibitors

Not only that, but mice that experienced complete tumor regression also showed long-term immune memory

Dr.

Reference materials:

[1] A peptide-drug conjugate that targets the acidic environment of cancer cells may improve the efficacy of immunotherapy.

(The original text has been deleted)